Publications by authors named "Caitlin Pretz"
Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality in the United States. Frequent exacerbations result in higher use of emergency services and hospitalizations, leading to poor patient outcomes and high costs.
Objective: Demonstrate the feasibility of a multimodal, digitally enhanced remote monitoring, treatment, and tele-pulmonary rehabilitation intervention among patients with COPD.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) is a prevalent and serious condition, highlighting the need for effective care approaches like pulmonary rehabilitation and early intervention during symptom flare-ups.
- The Healthy at Home study aims to explore a new digital care model for COPD patients over a 6-month period, recruiting 100 participants for its pilot phase.
- Participants will use technology like smartwatches and apps to monitor their symptoms and health data, allowing researchers to gain insights into disease behavior and improve care responses.
Article Synopsis
- The study analyzed the effectiveness of rapid and PCR tests for detecting SARS-CoV-2 after symptom onset and exposure among various populations in the U.S. between October 2021 and February 2022.
- Findings showed that test positivity was highest two days after symptoms began and six days after exposure, with Ag-RDTs detecting around 84.9% of infections within four days of symptoms.
- Results indicated no significant differences in test performance based on vaccination status, age, sex, or virus variant, but asymptomatic individuals had lower Ag-RDT positivity rates compared to those with symptoms.
Chronic Obstructive Pulmonary Disease (COPD) is a common, costly, and morbid condition. Pulmonary rehabilitation, close monitoring, and early intervention during acute exacerbations of symptoms represent a comprehensive approach to improve outcomes, but the optimal means of delivering these services is uncertain. Logistical, financial, and social barriers to providing healthcare through face-to-face encounters, paired with recent developments in technology, have stimulated interest in exploring alternative models of care.
View Article and Find Full Text PDFBackground: The performance of rapid antigen tests (Ag-RDTs) for screening asymptomatic and symptomatic persons for SARS-CoV-2 is not well established.
Objective: To evaluate the performance of Ag-RDTs for detection of SARS-CoV-2 among symptomatic and asymptomatic participants.
Design: This prospective cohort study enrolled participants between October 2021 and January 2022.
Background: Rapid antigen detection tests (Ag-RDT) for SARS-CoV-2 with emergency use authorization generally include a condition of authorization to evaluate the test's performance in asymptomatic individuals when used serially. We aim to describe a novel study design that was used to generate regulatory-quality data to evaluate the serial use of Ag-RDT in detecting SARS-CoV-2 virus among asymptomatic individuals.
Methods: This prospective cohort study used a siteless, digital approach to assess longitudinal performance of Ag-RDT.
Background: The performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) in temporal relation to symptom onset or exposure is unknown, as is the impact of vaccination on this relationship.
Objective: To evaluate the performance of Ag-RDT compared with RT-PCR based on day after symptom onset or exposure in order to decide on 'when to test'.
Design Setting And Participants: The Test Us at Home study was a longitudinal cohort study that enrolled participants over 2 years old across the United States between October 18, 2021 and February 4, 2022.
Background: It is important to document the performance of rapid antigen tests (Ag-RDTs) in detecting SARS-CoV-2 variants.
Objective: To compare the performance of Ag-RDTs in detecting the Delta (B.1.
Background: The ongoing SARS-CoV-2 pandemic necessitates the development of accurate, rapid, and affordable diagnostics to help curb disease transmission, morbidity, and mortality. Rapid antigen tests are important tools for scaling up testing for SARS-CoV-2; however, little is known about individuals' use of rapid antigen tests at home and how to facilitate the user experience.
Objective: This study aimed to describe the feasibility and acceptability of serial self-testing with rapid antigen tests for SARS-CoV-2, including need for assistance and the reliability of self-interpretation.
Background: Performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) varies over the course of an infection, and their performance in screening for SARS-CoV-2 is not well established. We aimed to evaluate performance of Ag-RDT for detection of SARS-CoV-2 for symptomatic and asymptomatic participants.
Methods: Participants >2 years old across the United States enrolled in the study between October 2021 and February 2022.
Background: Rapid antigen tests (Ag-RDT) for SARS-CoV-2 with Emergency Use Authorization generally include a condition of authorization to evaluate the test's performance in asymptomatic individuals when used serially.
Objective: To describe a novel study design to generate regulatory-quality data to evaluate serial use of Ag-RDT in detecting SARS-CoV-2 virus among asymptomatic individuals.
Design: Prospective cohort study using a decentralized approach.
Article Synopsis
- * Out of 5,506 eligible participants, 153 tested positive via RT-PCR (61 for Delta, 92 for Omicron), with only 23.5% testing Ag-RDT positive on the same day and 54.9% within 48 hours, showing no significant difference in sensitivity between the two variants.
- * The findings suggest that while Ag-RDT performance is slightly better for Omicron, the differences are not statistically significant, and a subset of participants remained Ag-RDT negative despite testing positive